Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1239 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Atezolizumab with chemotherapy for treating recurrent triple-negative breast cancer	Atezolizumab (Tecentriq; MPDL3280A) , Chemotherapy	Breast cancer	Breast Cancer	2022	View \| Download
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-containing chemotherapy and one programmed death-ligand 1 checkpoint inhibitor	Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Atezolizumab with cabozantinib for previously treated metastatic castration-resistant prostate cancer	Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Prostate cancer	Male Reproductive Cancer	2022	View \| Download
Atezolizumab with cabozantinib for advanced renal cell carcinoma after 1 therapy	Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Renal cell carcinoma (RCC)	Renal Cancer	2022	View \| Download
Atezolizumab with bevacizumab for patients with resected or ablated hepatocellular carcinoma who are at high risk for disease recurrence	Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download
Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer – first line	Atezolizumab (Tecentriq; MPDL3280A)	Urothelial cancer	Urological Cancer	2020	View \| Download
Atezolizumab in combination with Nab-paclitaxel for unresectable, locally advanced or metastatic triple-negative breast cancer – first line	Atezolizumab (Tecentriq; MPDL3280A) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007)	Breast cancer	Breast Cancer	2018	View \| Download
Atezolizumab in combination with nab-paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer	Atezolizumab (Tecentriq; MPDL3280A) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007)	Breast cancer	Breast Cancer	2018	View \| Download
Atezolizumab in combination with cobimetinib for BRAF wild-type metastatic melanoma – first line	Atezolizumab (Tecentriq; MPDL3280A) , Cobimetinib (Cotellic; GDC-0973; cobimetinib hemifumarate)	Melanoma	Skin Cancer	2018	View \| Download
Atezolizumab in combination with chemotherapy for non-small-cell lung cancer- neoadjuvant and adjuvant	Atezolizumab (Tecentriq; MPDL3280A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download